CUA Educational Content

The evolving landscape of first line therapy for locally advanced / metastatic urothelial cancer

Moderator: Christina Canil

Speaker: Daniel Sperlich

Objectives

By the end of this program, participants can expect to:

  • Interpret current evidence to inform first-line treatment strategies for patients with locally advanced or metastatic urothelial carcinoma (mUC).
  • Evaluate key clinical factors, including patient characteristics and toxicity considerations, to support individualized treatment decisions.
  • Apply practical approaches to sequencing, toxicity management, and personalized care using real-world patient scenarios.
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

-------------------------------------

This program has received financial support from EMD Serono in the form of an educational grant.
 

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy